GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Telix Pharmaceuticals Limited TLX · USD

Health Care · US listing · 🇺🇸 United States

Compare

9.89

+2.70%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price targets

Brokers' own targets, 19 Aug 2026. Not our view.

Low
18.00
Average
18.00
Median
18.00
High
18.00

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028FY2029FY2030
Revenue$1.41bn$1.82bn$2.13bn$2.59bn$2.39bn
Revenue, highest$1.45bn$1.90bn$2.46bn$2.79bn$2.58bn
Revenue, lowest$1.39bn$1.76bn$1.97bn$2.49bn$2.30bn
Earnings per share0.120.070.341.681.14
Earnings per share, highest0.180.071.071.851.26
Earnings per share, lowest0.090.050.061.601.08
Analysts106944

Earnings against forecasts

Earnings per share by fiscal quarter

Q2 2026Q4 2025Q2 2025Q4 2024Q2 2024Q4 2023
Forecast0.040.030.130.090.090.05
Reported0.11-0.01-0.010.110.060.04
Difference+140.3%-135.4%-105.1%+22.5%-33.2%-24.5%

Rating changes

Latest broker notes

  • HC Wainwright & Co.Buy
  • CitigroupBuy
  • WedbushOutperform
  • WedbushOutperform
  • HC Wainwright & Co.Buy
  • WedbushOutperform
  • HC Wainwright & Co.Buy
  • CitigroupBuy
  • HC Wainwright & Co.Buy
  • HC Wainwright & Co.Buy
  • UBSBuy
  • HC Wainwright & Co.Buy

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

3 / 10

Revenue growth 43.6% a year over 10 years. Return on equity -1.7%.

Model fair value

15.17

From earnings 15.17, from revenue 23.37.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.